Cargando…

Low Frequency of Opportunistic Infections in Patients Receiving Vedolizumab in Clinical Trials and Post-Marketing Setting

BACKGROUND: Vedolizumab (ENTYVIO) is a humanized α(4)β(7) integrin antagonist approved for the treatment of inflammatory bowel disease, which selectively blocks gut-specific lymphocyte trafficking. We evaluated the risk of opportunistic infections of interest in patients treated with vedolizumab. ME...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ng, Siew C, Hilmi, Ida Normiha, Blake, Aimee, Bhayat, Fatima, Adsul, Shashi, Khan, Qasim Rana, Wu, Deng-Chyang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Original Clinical Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6185254/ https://www.ncbi.nlm.nih.gov/pubmed/30312414 http://dx.doi.org/10.1093/ibd/izy153

Ejemplares similares

Efficacy and safety of vedolizumab in Crohn’s disease in patients from Asian countries in the GEMINI 2 study
por: Banerjee, Rupa, et al.
Publicado: (2021)

Efficacy and safety of vedolizumab in ulcerative colitis in patients from Asian countries in the GEMINI 1 study
por: Ooi, Choon Jin, et al.
Publicado: (2021)

Vedolizumab use in patients with inflammatory bowel diseases undergoing surgery: clinical trials and post-marketing experience
por: Shen, Bo, et al.
Publicado: (2019)

Respiratory Tract Infections in Patients With Inflammatory Bowel Disease: Safety Analyses From Vedolizumab Clinical Trials
por: Feagan, Brian G, et al.
Publicado: (2018)

What Is the Risk of Progressive Multifocal Leukoencephalopathy in Patients With Ulcerative Colitis or Crohn’s Disease Treated With Vedolizumab?
por: Card, Timothy, et al.
Publicado: (2018)

Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn’s Disease or Ulcerative Colitis
por: Vermeire, Séverine, et al.
Publicado: (2020)

Vedolizumab treatment persistence and safety in a 2‐year data analysis of an extended access programme
por: Danese, Silvio, et al.
Publicado: (2020)

Swallow syncope: a case report and review of literature
por: Siew, Kelvin Shenq Woei, et al.
Publicado: (2019)

Ulcerative colitis successfully treated with vedolizumab in the presence of comorbid opportunistic infections: a case report
por: Oki, Yusuke, et al.
Publicado: (2023)

Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials
por: Feagan, Brian G, et al.
Publicado: (2019)

Measuring Serum Vedolizumab and Vedolizumab Antibodies: Comparison of Commercial Assays with the Vedolizumab Clinical Development Assay
por: Vande Casteele, Niels, et al.
Publicado: (2023)

Uptake of a Switching Program for Patients Receiving Intravenous Infliximab and Vedolizumab to Subcutaneous Preparations
por: Burdge, Gemma, et al.
Publicado: (2022)

Vedolizumab-Associated Hypereosinophilia and Hepatoxicity
por: De Marco, Davide, et al.
Publicado: (2022)

Emergency colectomy for massive rectal bleeding in a patient with well-controlled ulcerative colitis receiving Vedolizumab
por: Ciortescu, Irina, et al.
Publicado: (2023)

Efficacy and safety of vedolizumab in elderly patients with inflammatory bowel disease: a matched case–control study
por: Shashi, Preeti, et al.
Publicado: (2019)

Vedolizumab in the treatment of Crohn’s disease of the pouch
por: Khan, Freeha, et al.
Publicado: (2018)

Vedolizumab for chronic antibiotic-refractory pouchitis
por: Singh, Amandeep, et al.
Publicado: (2019)

The Early Experience With Vedolizumab in the United States
por: Kochar, Bharati, et al.
Publicado: (2019)

Combination of vedolizumab and immunomodulators in ulcerative colitis
por: Pinton, P
Publicado: (2021)

Successful treatment with vedolizumab in an adolescent with Crohn disease who had developed active pulmonary tuberculosis while receiving infliximab
por: Choi, Sujin, et al.
Publicado: (2021)

Safety and Effectiveness of Vedolizumab in Patients with Moderate-to-Severe Ulcerative Colitis: An Interim Analysis of a Japanese Post-Marketing Surveillance Study
por: Matsuoka, Katsuyoshi, et al.
Publicado: (2023)

Chronic Cholestatic Liver Injury Attributable to Vedolizumab
por: Stine, Jonathan G., et al.
Publicado: (2016)

A Case of Evan's Syndrome Induced by Vedolizumab
por: Jen, Henry, et al.
Publicado: (2019)

The safety of vedolizumab for ulcerative colitis and Crohn's disease
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017)

Predicting Response to Vedolizumab in Inflammatory Bowel Disease
por: Meserve, Joseph, et al.
Publicado: (2020)

Vedolizumab Therapy in Refractory Enteropathy Associated With CVID
por: Johnson, Dane, et al.
Publicado: (2021)

Acute Chest Pain as an Infusion Reaction to Vedolizumab
por: Levartovsky, Asaf, et al.
Publicado: (2022)

Vedolizumab for induction and maintenance of remission in Crohn's disease
por: Hui, Samuel, et al.
Publicado: (2023)

Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: management
por: Park, Dong Il, et al.
Publicado: (2018)

Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment
por: Park, Dong Il, et al.
Publicado: (2018)

Association Between Vedolizumab Levels, Anti-vedolizumab Antibodies, and Endoscopic Healing Index in a Large Population of Patients with Inflammatory Bowel Diseases
por: Yarur, Andres J., et al.
Publicado: (2020)

Vedolizumab does not increase risk of clostridium difficile infection in patients with inflammatory bowel disease using vedolizumab: A retrospective cohort study
por: Saad Alshahrani, Abdulaziz, et al.
Publicado: (2023)

Frequency and distribution patterns of opportunistic infections associated with HIV/AIDS in Uganda
por: Rubaihayo, John, et al.
Publicado: (2016)

Patient considerations in the management of ulcerative colitis – role of vedolizumab
por: Kothari, Megha, et al.
Publicado: (2015)

Vedolizumab as a Potential Culprit in the Development of Ovarian Teratoma?
por: Trieu, Judy A., et al.
Publicado: (2017)

A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab
por: Rosario, Maria, et al.
Publicado: (2017)

Use of vedolizumab in a patient with chronic and refractory pouchitis
por: Orfanoudaki, Eleni, et al.
Publicado: (2018)

The Use of Vedolizumab in Patients with Concomitant Cirrhosis and Crohn’s Disease
por: Kapila, Nikhil, et al.
Publicado: (2018)

Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis
por: Bergqvist, Viktoria, et al.
Publicado: (2017)

Long‐term safety of vedolizumab for inflammatory bowel disease
por: Loftus, Edward V., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pc3sn46kd7kpbn8433tbd8kc7c